PFM Health Sciences’s Ascendis Pharma A/S ASND Stock Holding History

PFM Health Sciences’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,400	Closed	-$5.12M	–	100
2026 Q1	$5.12M	Buy	+22,400	New	+$5.02M	0.47%	63

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PFM Health Sciences's ASND Position: Q2 2026 in Review

PFM Health Sciences increased its Ascendis Pharma A/S (ASND) stake by 53% in Q2 2026, buying an estimated $19M and bringing the position to 233,171 shares worth $62.2M. The position accounts for 5.34% of the portfolio, ranked #1.

PFM Health Sciences first reported a position in ASND in Q4 2018 and has held it in 10 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

PFM Health Sciences held 233,171 shares of Ascendis Pharma A/S worth $62.2M as of Q2 2026.
PFM Health Sciences bought 81,137 Ascendis Pharma A/S shares in Q2 2026, an estimated $19M.
Ascendis Pharma A/S made up 5.34% of PFM Health Sciences's portfolio in Q2 2026, its #1 holding.
PFM Health Sciences first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 10 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.